AbbVie

News

AbbVie bids to join the BCMA crowd with etentamig

AbbVie has filed for FDA approval of its BCMAxCD3 bispecific etentamig in multiple myeloma, a key pillar of its expansion into oncology.

News

ESMO26: Lilly's sofe-m ADC stakes a claim in ovarian cancer

Eli Lilly's first major readout at ESMO comes from a phase 1 trial of its FRα-targeting sofe-m in platinum-sensitive ovarian cancer (PSOC).

News

UEGW delegates hear of strides forward in IBD treatment

Trials of Lilly's Omvoh, Gilead's emvistegrast, Takeda's Entyvio, AbbVie's ABBV-466, and Sanofi/Teva's duvakitug are highlights of UEGW.

News

Apogee buy delivers eczema trial win for AbbVie

AbbVie's long-acting IL-13 inhibitor zumilokibart, part of its $10.9bn Apogee buy, has shown efficacy in atopic dermatitis and will move into phase 3.

News

AbbVie's Cerevel takeover delivers Parkinson's approval

The first drug from AbbVie's $8.7 billion takeover of Cerevel two years ago, Parkinson's disease therapy Juvmo, has won FDA approval.

News

Iambic files IPO after signing up AbbVie as new partner

In the space of a day, Iambic has filed an IPO, released the latest version of its AI platform, and signed a multi-year alliance with AbbVie.

AbbVie bids to join the BCMA crowd with etentamig

ESMO26: Lilly's sofe-m ADC stakes a claim in ovarian cancer

UEGW delegates hear of strides forward in IBD treatment

Apogee buy delivers eczema trial win for AbbVie

AbbVie's Cerevel takeover delivers Parkinson's approval

Iambic files IPO after signing up AbbVie as new partner

Aspen, Bambusa close IPOs as Corxel takes SPAC route

Discover a new era of healthcare panel engagement: Grounded ...

AbbVie

Editor's Picks